Success After a Century of Failures: Inside Moderna and Merck's Cancer Vaccine Breakthrough
The personalized mRNA shot, Intismeran, helped more than 1,000 patients stay cancer-free longer and lowered the risk of spread, the companies said.
- Merck and Moderna announced positive interim phase three clinical trial results for a personalized melanoma vaccine called Intismeran, which significantly extended cancer-free survival compared to existing immunotherapy alone.
- Scientists created the personalized vaccine by surgically collecting tumor samples, sequencing their DNA, and using mRNA technology to train each patient's immune system to recognize and attack malignant cells unique to their cancer.
- The trial enrolled more than 1,000 patients with high-risk melanoma, combining Intismeran with Keytruda following surgery to prevent tumor recurrence and reduce disease spread to other organs.
- Cancer experts characterized the preliminary findings as encouraging, yet the results remain unreviewed by independent researchers and require regulatory approval before becoming available through the NHS.
- Comprehensive trial findings are scheduled for presentation in October, as both companies develop similar personalized vaccine candidates for lung, bladder, and kidney cancers.
36 Articles
36 Articles
Vaccine breakthrough stops cancer returning in trial
A personalized vaccine combined with an immunotherapy drug extended cancer-free survival in melanoma patients during a trial, though full results remain pending peer review and regulatory approval. The post Vaccine breakthrough stops cancer returning in trial appeared first on RocketNews.
An experimental vaccine against melanoma has just produced encouraging results in a Phase 3 clinical trial. Customised for each patient, it could reduce the risk of recurrence after surgery.This article Skin cancer vaccine: a promising new therapeutic pathway appeared first on Full Life.
Moderna Shares Drop 3.4% with $55 Billion Valuation Raising Questions About Cancer Vaccine Progress
CAMBRIDGE, Massachusetts, August 30, 2026, 16:12 (ET) Shares of Moderna dropped 3.35% on Friday, with trading volume reaching 178% of its average level.The company is still over 130% higher following its melanoma vaccine results.Analysts project cancer-vaccine revenues will top $1 billion by 2030 and reach $3 billion by 2035.Revenue in the second quarter reached $145…
"Intismeran Combines Immunotherapy and mRNA to Fight Skin Cancer"
An innovative treatment for skin cancer that merges immunotherapy with mRNA vaccine technology has shown promising outcomes in a late-phase trial, as per a joint announcement by pharmaceutical giants Merck and Moderna on Wednesday. The combined therapy, known as intismeran, outperformed standalone immunotherapy in curbing melanoma recurrence and preventing its spread in post-surgery melanoma patients. […] The post “Intismeran Combines Immunother…
Moderna and Merck’s personalized mRNA-based therapy has met key goals in a large-scale, phase III trial. The experimental treatment, combined with the immunotherapy Keytruda, reduced the risk of melanoma recurrence and distant spread. After more than a century of largely unsuccessful attempts, the first late-phase clinical trial of a therapeutic mRNA-based cancer vaccine has ended with a positive result. Moderna and […] The post Personalized can…
Coverage Details
Bias Distribution
- 87% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
